J Hematol Oncol. 2012 Jun 26;5:33. doi: 10.1186/1756-8722-5-33.
Autologous stem cell transplantation (ASCT) is the gold standard therapy for suitable multiple myeloma (MM) patients after induction with high dose therapy. To date, the evidence of a reliable marker of prognosis in these cases remains scarce. Our aim was to evaluate appearance of unrelated atypical serum immunofixation patterns (ASIPs) as a marker of prognosis in MM patients submitted to ASCT. We retrospectively analysed data from 65 patients. Interestingly, we observed that presence of ASIPs was associated with longer progression-free survival and longer overall survival. Our results suggested that presence of ASIPs could be a novel marker of good prognosis in MM patients submitted to ASCT.
自体干细胞移植（ASCT）是适合的多发性骨髓瘤（MM）患者在接受高剂量治疗后的标准治疗方法。迄今为止，这些病例中可靠预后标志物的证据仍然很少。我们的目的是评估 ASCT 后 MM 患者出现非相关非典型血清免疫固定电泳图谱（ASIPs）作为预后标志物的情况。我们回顾性分析了 65 例患者的数据。有趣的是，我们观察到存在 ASIPs 与更长的无进展生存期和更长的总生存期相关。我们的结果表明，ASCT 后 MM 患者存在 ASIPs 可能是一种新的预后良好标志物。
